|
LOC646762 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.43950423697947E-11 |
| Normal-vs-Stage2 |
1.381170E-03 |
| Normal-vs-Stage3 |
7.67279999980275E-07 |
| Normal-vs-Stage4 |
1.74415999999455E-05 |
| Stage1-vs-Stage2 |
5.243000E-01 |
| Stage1-vs-Stage3 |
9.521600E-02 |
| Stage1-vs-Stage4 |
6.153000E-01 |
| Stage2-vs-Stage3 |
5.577200E-01 |
| Stage2-vs-Stage4 |
8.297800E-01 |
| Stage3-vs-Stage4 |
3.071600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66622271535743E-12 |
| Normal-vs-AfricanAmerican |
4.541200E-03 |
| Normal-vs-Asian |
1.803020E-03 |
| Caucasian-vs-AfricanAmerican |
8.074600E-01 |
| Caucasian-vs-Asian |
8.128600E-01 |
| AfricanAmerican-vs-Asian |
7.124000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.85550000031398E-07 |
| Normal-vs-Female |
1.64668279012403E-12 |
| Male-vs-Female |
4.612200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.34069999546682E-09 |
| Normal-vs-Age(41-60Yrs) |
1.34499966719659E-10 |
| Normal-vs-Age(61-80Yrs) |
1.355500E-04 |
| Normal-vs-Age(81-100Yrs) |
3.360000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.213800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.863400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.216400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.405000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.379800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.279400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.698000E-01 |
| Classical-VS-Follicular |
1.646960E-04 |
| Classical-VS-Other |
8.286000E-01 |
| Classical-VS-Normal |
1.11022302462516E-16 |
| Tall-VS-Follicular |
5.847400E-01 |
| Tall-VS-Other |
8.700400E-01 |
| Tall-VS-Normal |
1.731580E-01 |
| Follicular-VS-Other |
3.050400E-01 |
| Follicular-VS-Normal |
2.596400E-03 |
| Other-VS-Normal |
1.456030E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03310000554302E-08 |
| Normal-vs-N1 |
2.349299999993E-05 |
| N0-vs-N1 |
6.013200E-01 |
|
|
